Inflammatory Response in the CNS: Friend or Foe?

Molecular Neurobiology

Volumn 54, Issue 10, 2017, Pages 8071-8089

  Sochocka, Marta ^a   Diniz, Breno Satler ^b   Leszek, Jerzy ^c  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Cytokines; Immune response in the CNS; Microglia activation; miRNA; Neurodegeneration; Neuroinflammation

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MICRORNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN P53; RESISTIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; AGING; ASTROCYTE; CELL ACTIVATION; CYTOKINE RELEASE; GLIA CELL; HUMAN; INNATE IMMUNITY; MICROGLIA; MOLECULAR INTERACTION; NERVE CELL DIFFERENTIATION; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEURITE OUTGROWTH; NEUROPROTECTION; OXIDATIVE STRESS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVIEW; ANIMAL; INFLAMMATION; METABOLISM; NERVE CELL; PATHOLOGY;

ANIMALS; ASTROCYTES; HUMANS; INFLAMMATION; MICROGLIA; NEURONS; NF-KAPPA B; TOLL-LIKE RECEPTORS;

EID: 84997496789     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-016-0297-1     Document Type: Review

References (181)

1. Diack AB, Alibhai JD, Barron R, Bradford B, Piccardo P, Manson JC (2016) Insights into mechanisms of chronic neurodegeneration. Int J Mol Sci 17(1)
2. Chen W-W, Zhang X, Huang W-J (2016) Role of neuroinflammation in neurodegenerative diseases (review). Mol Med Rep 13:3391–3396
3. Kohan R, Cismondi IA, Oller-Ramirez AM, Guelbert N, Anzolini TV, Alonso G et al (2011) Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses. Curr Pharm Biotechnol 12:867–883
4. DiSabato D, Quan N, Godbout JP (2016) Neuroinflammation: the devil is in the details. J Neurochem. doi:10.1111/jnc.13607
5. Waisman A, Liblau RS, Becher B (2015) Innate and adaptive immune responses in the CNS. Lancet Neurol 14:945–955
6. Headland SE, Norling LV (2015) The resolution of inflammation: principles and challenges. Semin Immunol 27:149–160
7. Całkosiński I, Dobrzyński M, Całkosińska M, Seweryn E, Bronowicka-Szydełko A et al (2009) Characterization of an inflammatory response. Post Hig Med Dosw (online) 63:395–408
8. Franceschi C, Campisi J (2014) Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci 69(Suppl 1):S4–S9
9. Maskrey BH, Megson IL, Whitfield PD, Rossi AG (2011) Mechanisms of resolution of inflammation: a focus on cardiovascular disease. Arterioscler Thromb Vasc Biol 31:1001–1006
10. Shaw AC, Goldstein DR, Montgomery RR (2013) Age-dependent dysregulation of innate immunity. Nat Rev Immunol 13:875–887
11. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F et al (2007) Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 128:92–105
12. Salvioli S, Capri M, Valensin S, Tieri P, Monti D, Ottaviani E et al (2006) Inflamm-aging, cytokines and aging: state of the art, new hypotheses on the role of mitochondria and new perspectives from systems biology. Curr Pharm Des 12:3161–3171
13. Batra A, Siegmund B (2012) The role of visceral fat. Dig Dis 30:70–74
14. Palmer AK, Tchkonia T, LeBrasseur NK, Chini EN, Xu M, Kirkland JL (2015) Cellular senescence in type 2 diabetes: a therapeutic opportunity. Diabetes 64:2289–2298
15. Skowrońska B, Fichna M, Fichna P (2005) The role of adipose tissue in the endocrine system. Endokrynol Otyłość Zaburz Przem Materii 1:21–29
16. Kim S-H, Chung J, Song S-W, Jung WS, Lee Y-A, Kim H-N (2016) Relationship between deep subcutaneous abdominal adipose tissue and metabolic syndrome: a case control study. Diabetol Metab Syndr 8:10
17. Kiliaan AJ, Arnoldussen IAC, Gustafson DR (2014) Adipokines: a link between obesity and dementia? Lancet Neurol 13:913–923
18. Li X, Song D, Leng SX (2015) Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment. Clin Interv Aging 10:549–560
19. van Dijk G, van Heijningen S, Reijne AC, Nyakas C, van der Zee EA, Eisel ULM (2015) Integrative neurobiology of metabolic diseases, neuroinflammation, and neurodegeneration. Front Neurosci 9:173
20. Kim B, Feldman EL (2015) Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Exp Mol Med 47:e149
21. Weltevrede M, Eilers R, de Melker HE, van Baarle D (2016) Cytomegalovirus persistence and T-cell immunosenescence in people aged fifty and older: a systematic review. Exp Gerontol 77:87–95
22. Bauer ME, Fuente MD la (2016) The role of oxidative and inflammatory stress and persistent viral infections in immunosenescence. Mech Ageing Dev 7
23. Nasi M, Pinti M, De Biasi S, Gibellini L, Ferraro D, Mussini C et al (2014) Aging with HIV infection: a journey to the center of inflammAIDS, immunosenescence and neuroHIV. Immunol Lett 162(1 Pt B):329–333
24. Sansoni P, Vescovini R, Fagnoni F, Biasini C, Zanni F, Zanlari L et al (2008) The immune system in extreme longevity. Exp Gerontol 43:61–65
25. Johnson RW, Alvarez-Pasquin M-J, Bijl M, Franco E, Gaillat J, Clara JG et al (2015) Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines 3:109–120
26. Heneka MT, Carson MJ, Khoury JE, Landreth GE, Brosseron F, Feinstein DL et al (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14:388–405
27. Morales I, Guzmán-Martínez L, Cerda-Troncoso C, Farías GA, Maccioni RB (2014) Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci 8:112
28. Lim SL, Rodriguez-Ortiz CJ, Kitazawa M (2015) Infection, systemic inflammation, and Alzheimer’s disease. Microbes Infect 17:549–556
29. Schwartz M, Baruch K (2014) The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J 33:7–22
30. Russo MV, McGavern DB (2015) Immune surveillance of the CNS following infection and injury. Trends Immunol 36:637–650
31. Walsh JG, Muruve DA, Power C (2014) Inflammasomes in the CNS. Nat Rev Neurosci 15:84–97
32. Barichello T, Generoso JS, Goularte JA, Collodel A, Pitcher MR, Simões LR et al (2015) Does infection-induced immune activation contribute to dementia? Aging Dis 6:342–348
33. Khandelwal PJ, Herman AM, Moussa CE-H (2011) Inflammation in the early stages of neurodegenerative pathology. J Neuroimmunol 238:1–11
34. Tarr AJ, Liu X, Reed NS, Quan N (2014) Kinetic characteristics of euflammation: the induction of controlled inflammation without overt sickness behavior. Brain Behav Immun 42:96–108
35. Liu X, Nemeth DP, Tarr AJ, Belevych N, Syed ZW, Wang Y et al (2016) Euflammation attenuates peripheral inflammation-induced neuroinflammation and mitigates immune-to-brain signaling. Brain Behav Immun 54:140–148
36. González H, Pacheco R (2014) T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases. J Neuroinflammation 11:201
37. Lun MP, Monuki ES, Lehtinen MK (2015) Development and functions of the choroid plexus-cerebrospinal fluid system. Nat Rev Neurosci 16:445–457
38. Schwartz M, Shechter R (2010) Protective autoimmunity functions by intracranial immunosurveillance to support the mind: the missing link between health and disease. Mol Psychiatry 15:342–354
39. Schwartz M, Raposo C (2014) Protective autoimmunity: a unifying model for the immune network involved in CNS repair. Neurosci Rev J Bringing Neurobiol Neurol Psychiatry 20:343–358
40. Rezaie P, Male D (2002) Mesoglia & microglia—a historical review of the concept of mononuclear phagocytes within the central nervous system. J Hist Neurosci 11:325–374
41. Ginhoux F, Prinz M (2015) Origin of microglia: current concepts and past controversies. Cold Spring Harb Perspect Biol 7:a020537
42. Hristovska I, Pascual O (2015) Deciphering resting microglial morphology and process motility from a synaptic prospect. Front Integr Neurosci 9:73
43. Correale J (2014) The role of microglial activation in disease progression. Mult Scler Houndmills Basingstoke Engl 20:1288–1295
44. Hernandez-Ontiveros DG, Tajiri N, Acosta S, Giunta B, Tan J, Borlongan CV (2013) Microglia activation as a biomarker for traumatic brain injury. Front Neurol 4:30
45. Ginhoux F, Lim S, Hoeffel G, Low D, Huber T (2013) Origin and differentiation of microglia. Front Cell Neurosci 7:45
46. Nayak D, Roth TL, McGavern DB (2014) Microglia development and function. Annu Rev Immunol 32:367–402
47. Wu Y, Dissing-Olesen L, MacVicar BA, Stevens B (2015) Microglia: dynamic mediators of synapse development and plasticity. Trends Immunol 36:605–613
48. Neumann H, Kotter MR, Franklin RJM (2009) Debris clearance by microglia: an essential link between degeneration and regeneration. Brain J Neurol 132:288–295
49. Bahrini I, Song J, Diez D, Hanayama R (2015) Neuronal exosomes facilitate synaptic pruning by up-regulating complement factors in microglia. Sci Rep 5:7989
50. Bátiz LF, Castro MA, Burgos PV, Velásquez ZD, Muñoz RI, Lafourcade CA et al (2015) Exosomes as novel regulators of adult neurogenic niches. Front Cell Neurosci 9:501
51. Pegtel DM, Peferoen L, Amor S (2014) Extracellular vesicles as modulators of cell-to-cell communication in the healthy and diseased brain. Philos Trans R Soc Lond B Biol Sci 369(1652)
52. Frühbeis C, Fröhlich D, Kuo WP, Amphornrat J, Thilemann S, Saab AS et al (2013) Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-neuron communication. PLoS Biol 11:e1001604
53. Bellingham SA, Guo BB, Coleman BM, Hill AF (2012) Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front Physiol 3:124
54. Turola E, Furlan R, Bianco F, Matteoli M, Verderio C (2012) Microglial microvesicle secretion and intercellular signaling. Front Physiol 3:149
55. Properzi F, Logozzi M, Fais S (2013) Exosomes: the future of biomarkers in medicine. Biomark Med 7:769–778
56. Wang X, Zhao L, Zhang J, Fariss RN, Ma W, Kretschmer F et al (2016) Requirement for microglia for the maintenance of synaptic function and integrity in the mature retina. J Neurosci 36:2827–2842
57. Gertig U, Hanisch U-K (2014) Microglial diversity by responses and responders. Front Cell Neurosci 8:101
58. Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease—a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2:a006346
59. Streit WJ, Xue Q-S (2009) Life and death of microglia. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol 4:371–379
60. Luo X-G, Chen S-D (2012) The changing phenotype of microglia from homeostasis to disease. Transl Neurodegener 1:9
61. von Bernhardi R, Eugenín-von Bernhardi L, Eugenín J (2015) Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci 7:124
62. Lynch MA (2014) The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer’s disease. Immunology 141:292–301
63. Colton CA (2009) Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol 4:399–418
64. Walker DG, Lue L-F (2015) Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains. Alzheimers Res Ther 7:56
65. Cappellano G, Carecchio M, Fleetwood T, Magistrelli L, Cantello R, Dianzani U et al (2013) Immunity and inflammation in neurodegenerative diseases. Am J Neurodegener Dis 2:89–107
66. Heneka MT, Kummer MP, Latz E (2014) Innate immune activation in neurodegenerative disease. Nat Rev Immunol 14:463–477
67. Ferrini F, De Koninck Y (2013) Microglia control neuronal network excitability via BDNF signalling. Neural Plast 2013:429815
68. Alboni S, Maggi L (2015) Editorial: cytokines as players of neuronal plasticity and sensitivity to environment in healthy and pathological brain. Front Cell Neurosci 9:508
69. Sajja VSSS, Hlavac N, VandeVord PJ (2016) Role of glia in memory deficits following traumatic brain injury: biomarkers of glia dysfunction. Front Integr Neurosci 10:7
70. Camara ML, Corrigan F, Jaehne EJ, Jawahar MC, Anscomb H, Koerner H et al (2013) TNF-α and its receptors modulate complex behaviours and neurotrophins in transgenic mice. Psychoneuroendocrinology 38:3102–3114
71. Steinmetz CC, Turrigiano GG (2010) Tumor necrosis factor-α signaling maintains the ability of cortical synapses to express synaptic scaling. J Neurosci 30:14685–14690
72. Lull ME, Block ML (2010) Microglial activation and chronic neurodegeneration. Neurother J Am Soc Exp Neurother 7:354–365
73. Prinz M, Priller J (2014) Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci 15:300–312
74. Block ML, Hong J-S (2007) Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 35:1127–1132
75. Leszek J, Barreto GE, Gąsiorowski K, Koutsouraki E, Ávila-Rodrigues M, Aliev G (2016) Inflammatory mechanisms and oxidative stress as key factors responsible for progression of neurodegeneration: role of brain innate immune system. CNS Neurol Disord Drug Targets 15:329–336
76. Fischer R, Maier O (2015) Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. Oxidative Med Cell Longev 2015:610813
77. Sochocka M, Koutsouraki ES, Gasiorowski K, Leszek J (2013) Vascular oxidative stress and mitochondrial failure in the pathobiology of Alzheimer’s disease: a new approach to therapy. CNS Neurol Disord Drug Targets 12:870–881
78. Wu Z, Yu J, Zhu A, Nakanishi H (2016) Nutrients, microglia aging, and brain aging. Oxidative Med Cell Longev 2016:7498528
79. Varnum MM, Ikezu T (2012) The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer’s disease brain. Arch Immunol Ther Exp 60:251–266
80. Yu Z, Sun D, Feng J, Tan W, Fang X, Zhao M et al (2015) MSX3 switches microglia polarization and protects from inflammation-induced demyelination. J Neurosci 35:6350–6365
81. Cherry JD, Olschowka JA, O’Banion MK (2014) Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation 11:98
82. Cerbai F, Lana D, Nosi D, Petkova-Kirova P, Zecchi S, Brothers HM et al (2012) The neuron-astrocyte-microglia triad in normal brain ageing and in a model of neuroinflammation in the rat hippocampus. PLoS One 7:e45250
83. McGeer PL, McGeer EG (2015) Targeting microglia for the treatment of Alzheimer’s disease. Expert Opin Ther Targets 19:497–506
84. Latta CH, Brothers HM, Wilcock DM (2015) Neuroinflammation in Alzheimer’s disease; a source of heterogeneity and target for personalized therapy. Neuroscience 302:103–111
85. Moore CS, Rao VTS, Durafourt BA, Bedell BJ, Ludwin SK, Bar-Or A et al (2013) miR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization. Ann Neurol 74:709–720
86. Hamzei Taj S, Kho W, Riou A, Wiedermann D, Hoehn M (2016) MiRNA-124 induces neuroprotection and functional improvement after focal cerebral ischemia. Biomaterials 91:151–165
87. Ponomarev ED, Veremeyko T, Weiner HL (2013) MicroRNAs are universal regulators of differentiation, activation, and polarization of microglia and macrophages in normal and diseased CNS. Glia 61:91–103
88. Magistretti PJ, Ransom BR (2002) Astrocytes. Neuropsychopharmacology: the fifth generation of progress. In: Davis KL, Charney D, Coyle JT, Nemeroff C (eds). Williams and Wilkins, Philadelphia, Lippincott, pp 133–145
89. Steardo L, Bronzuoli MR, Iacomino A, Esposito G, Steardo L, Scuderi C (2015) Does neuroinflammation turn on the flame in Alzheimer’s disease? Focus on astrocytes. Front Neurosci 9:259
90. Messing A, Brenner M (2003) GFAP: functional implications gleaned from studies of genetically engineered mice. Glia 43:87–90
91. Tanaka KF, Takebayashi H, Yamazaki Y, Ono K, Naruse M, Iwasato T et al (2007) Murine model of Alexander disease: analysis of GFAP aggregate formation and its pathological significance. Glia 55:617–631
92. Mohn TC, Koob AO (2015) Adult astrogenesis and the etiology of cortical neurodegeneration. J Exp Neurosci 9(Suppl 2):25–34
93. Fuller S, Steele M, Münch G (2010) Activated astroglia during chronic inflammation in Alzheimer’s disease—do they neglect their neurosupportive roles? Mutat Res 690:40–49
94. Zhao J, O’Connor T, Vassar R (2011) The contribution of activated astrocytes to Aβ production: implications for Alzheimer’s disease pathogenesis. J Neuroinflammation 8:150
95. Efremova L, Chovancova P, Adam M, Gutbier S, Schildknecht S, Leist M (2016) Switching from astrocytic neuroprotection to neurodegeneration by cytokine stimulation. Arch Toxicol Apr 6
96. Villegas-Llerena C, Phillips A, Garcia-Reitboeck P, Hardy J, Pocock JM (2016) Microglial genes regulating neuroinflammation in the progression of Alzheimer’s disease. Curr Opin Neurobiol 36:74–81
97. Yoon S, Kim Y (2015) The role of immunity and neuroinflammation in genetic predisposition. Aims Genet 2:230–249
98. Salminen A, Ojala J, Suuronen T, Kaarniranta K, Kauppinen A (2008) Amyloid-beta oligomers set fire to inflammasomes and induce Alzheimer’s pathology. J Cell Mol Med 12:2255–2262
99. de Vasconcelos NM, Van Opdenbosch N, Lamkanfi M (2016) Inflammasomes as polyvalent cell death platforms. Cell Mol Life Sci CMLS 73:2335–2347
100. Liu L, Chan C (2014) The role of inflammasome in Alzheimer’s disease. Ageing Res Rev 15:6–15
101. Tan M-S, Yu J-T, Jiang T, Zhu X-C, Tan L (2013) The NLRP3 inflammasome in Alzheimer’s disease. Mol Neurobiol 48:875–882
102. Heneka MT, Golenbock DT, Latz E (2015) Innate immunity in Alzheimer’s disease. Nat Immunol 16:229–236
103. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE et al (2001) In-vivo measurement of activated microglia in dementia. Lancet Lond Engl 358:461–467
104. Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE et al (2008) Microglia, amyloid, and cognition in Alzheimer’s disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 32:412–419
105. Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R et al (2009) Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 72:56–62
106. Crack PJ, Bray PJ (2007) Toll-like receptors in the brain and their potential roles in neuropathology. Immunol Cell Biol 85:476–480
107. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol 11:373–384
108. Doi Y, Mizuno T, Maki Y, Jin S, Mizoguchi H, Ikeyama M et al (2009) Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid-beta neurotoxicity in in vitro and in vivo models of Alzheimer’s disease. Am J Pathol 175:2121–2132
109. Fassbender K, Walter S, Kühl S, Landmann R, Ishii K, Bertsch T et al (2004) The LPS receptor (CD14) links innate immunity with Alzheimer’s disease. FASEB J Off Publ Fed Am Soc Exp Biol 18:203–205
110. Kielian T (2006) Toll-like receptors in central nervous system glial inflammation and homeostasis. J Neurosci Res 83:711–730
111. Scholtzova H, Kascsak RJ, Bates KA, Boutajangout A, Kerr DJ, Meeker HC et al (2009) Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer’s disease-related pathology. J Neurosci 29:1846–1854
112. Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B et al (2012) TLR2 is a primary receptor for Alzheimer’s amyloid β peptide to trigger neuroinflammatory activation. J Immunol 188:1098–1107
113. Perkins ND (2007) Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8:49–62
114. Vigneron A, Vousden KH (2010) p53, ROS and senescence in the control of aging. Aging 2:471–474
115. Lucin KM, O’Brien CE, Bieri G, Czirr E, Mosher KI, Abbey RJ et al (2013) Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer’s disease. Neuron 79:873–886
116. Jaeger PA, Pickford F, Sun C-H, Lucin KM, Masliah E, Wyss-Coray T (2010) Regulation of amyloid precursor protein processing by the Beclin 1 complex. PLoS One 5:e11102
117. Salminen A, Kaarniranta K, Kauppinen A, Ojala J, Haapasalo A, Soininen H et al (2013) Impaired autophagy and APP processing in Alzheimer’s disease: the potential role of Beclin 1 interactome. Prog Neurobiol 106–107:33–54
118. Painter MM, Atagi Y, Liu C-C, Rademakers R, Xu H, Fryer JD et al (2015) TREM2 in CNS homeostasis and neurodegenerative disease. Mol Neurodegener 10:43
119. Boutajangout A, Wisniewski T (2013) The innate immune system in Alzheimer’s disease. Int J Cell Biol 2013:576383
120. Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML et al (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell 160:1061–1071
121. Jiang T, Zhang Y-D, Chen Q, Gao Q, Zhu X-C, Zhou J-S et al (2016) TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice. Neuropharmacology 105:196–206
122. Pottier C, Wallon D, Rousseau S, Rovelet-Lecrux A, Richard A-C, Rollin-Sillaire A et al (2013) TREM2 R47H variant as a risk factor for early-onset Alzheimer’s disease. J Alzheimers Dis JAD 35:45–49
123. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J et al (2013) Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med 368:107–116
124. Lill CM, Rengmark A, Pihlstrøm L, Fogh I, Shatunov A, Sleiman PM et al (2015) The role of TREM2 R47H as a risk factor for Alzheimer’s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson’s disease. Alzheimers Dement J Alzheimers Assoc 11:1407–1416
125. Rivest S (2015) TREM2 enables amyloid β clearance by microglia. Cell Res 25:535–536
126. Ulrich JD, Holtzman DM (2016) TREM2 function in Alzheimer’s disease and neurodegeneration. ACS Chem Neurosci 7:420–427
127. Colonna M, Wang Y (2016) TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci 17:201–207
128. Hamelin L, Lagarde J, Dorothée G, Leroy C, Labit M, Comley RA et al (2016) Early and protective microglial activation in Alzheimer’s disease: a prospective study using 18F-DPA-714 PET imaging. Brain J Neurol 139:1252–1264
129. Refolo V, Stefanowa N (2015) Microglia activation as a therapeutic target in multiple system atrophy: the timing, the good and the bad. Macrophage 2:e1065
130. Griffin WST, Mrak RE (2002) Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer’s disease. J Leukoc Biol 72:233–238
131. McNaull BBA, Todd S, McGuinness B, Passmore AP (2010) Inflammation and anti-inflammatory strategies for Alzheimer’s disease—a mini-review. Gerontology 56:3–14
132. Rubio-Perez JM, Morillas-Ruiz JM (2012) A review: inflammatory process in Alzheimer’s disease, role of cytokines. ScientificWorldJournal 2012:756357
133. McAfoose J, Baune BT (2009) Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 33:355–366
134. Delaby C, Gabelle A, Blum D, Schraen-Maschke S, Moulinier A, Boulanghien J et al (2015) Central nervous system and peripheral inflammatory processes in Alzheimer’s disease: biomarker profiling approach. Front Neurol 6:181
135. Zambrano A, Otth C, Maccioni RB, Concha II (2010) IL-3 controls tau modifications and protects cortical neurons from neurodegeneration. Curr Alzheimer Res 7:615–624
136. Zambrano A, Otth C, Mujica L, Concha II, Maccioni RB (2007) Interleukin-3 prevents neuronal death induced by amyloid peptide. BMC Neurosci 8:82
137. Natarajan C, Sriram S, Muthian G, Bright JJ (2004) Signaling through JAK2-STAT5 pathway is essential for IL-3-induced activation of microglia. Glia 45:188–196
138. Smith JA, Das A, Ray SK, Banik NL (2012) Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 87:10–20
139. Gordon S, Martinez FO (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32:593–604
140. Latta CH, Sudduth TL, Weekman EM, Brothers HM, Abner EL, Popa GJ et al (2015) Determining the role of IL-4 induced neuroinflammation in microglial activity and amyloid-β using BV2 microglial cells and APP/PS1 transgenic mice. J Neuroinflammation 12:41
141. Liu C, Cui G, Zhu M, Kang X, Guo H (2014) Neuroinflammation in Alzheimer’s disease: chemokines produced by astrocytes and chemokine receptors. Int J Clin Exp Pathol 7:8342–8355
142. Guillot-Sestier M-V, Doty KR, Gate D, Rodriguez J, Leung BP, Rezai-Zadeh K et al (2015) Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 85:534–548
143. Aloisi F, Penna G, Cerase J, Menéndez Iglesias B, Adorini L (1997) IL-12 production by central nervous system microglia is inhibited by astrocytes. J Immunol Baltim Md 1950 159:1604–1612
144. Vom Berg J, Prokop S, Miller KR, Obst J, Kälin RE, Lopategui-Cabezas I et al (2012) Inhibition of IL-12/IL-23 signaling reduces Alzheimer’s disease-like pathology and cognitive decline. Nat Med 18:1812–1819
145. Bishnoi RJ, Palmer RF, Royall DR (2015) Serum interleukin (IL)-15 as a biomarker of Alzheimer’s disease. PLoS One 10:e0117282
146. Rentzos M, Rombos A (2012) The role of IL-15 in central nervous system disorders. Acta Neurol Scand 125:77–82
147. Sutinen EM, Pirttilä T, Anderson G, Salminen A, Ojala JO (2012) Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid-β production in human neuron-like cells. J Neuroinflammation 9:199
148. Salani F, Ciaramella A, Bizzoni F, Assogna F, Caltagirone C, Spalletta G et al (2013) Increased expression of interleukin-18 receptor in blood cells of subjects with mild cognitive impairment and Alzheimer’s disease. Cytokine 61:360–363
149. Yasuoka S, Kawanokuchi J, Parajuli B, Jin S, Doi Y, Noda M et al (2011) Production and functions of IL-33 in the central nervous system. Brain Res 1385:8–17
150. Gadani SP, Walsh JT, Lukens JR, Kipnis J (2015) Dealing with danger in the CNS: the response of the immune system to injury. Neuron 87:47–62
151. Zheng C, Zhou X-W, Wang J-Z (2016) The dual roles of cytokines in Alzheimer’s disease: update on interleukins, TNF-α, TGF-β and IFN-γ. Transl Neurodegener 5:7
152. Sriram K, O’Callaghan JP (2007) Divergent roles for tumor necrosis factor-alpha in the brain. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol 2:140–153
153. Rocha NP, Teixeira AL, Coelho FM, Caramelli P, Guimarães HC, Barbosa IG et al (2012) Peripheral blood mono-nuclear cells derived from Alzheimer’s disease patients show elevated baseline levels of secreted cytokines but resist stimulation with β-amyloid peptide. Mol Cell Neurosci 49:77–84
154. Sastre M, Klockgether T, Heneka MT (2006) Contribution of inflammatory processes to Alzheimer’s disease: molecular mechanisms. Int J Dev Neurosci Off J Int Soc Dev Neurosci 24:167–176
155. Hsieh H-L, Yang C-M (2013) Role of redox signaling in neuroinflammation and neurodegenerative diseases. Biomed Res Int 2013:484613
156. Fischer R, Maier O, Siegemund M, Wajant H, Scheurich P, Pfizenmaier K (2011) A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death. PLoS One 6:e27621
157. Chiarini A, Dal Pra I, Whitfield JF, Armato U (2006) The killing of neurons by beta-amyloid peptides, prions, and pro-inflammatory cytokines. Ital J Anat Embryol Arch Ital Anat Ed Embriologia 111:221–246
158. Kempuraj D, Khan MM, Thangavel R, Xiong Z, Yang E, Zaheer A (2013) Glia maturation factor induces interleukin-33 release from astrocytes: implications for neurodegenerative diseases. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol 8:643–650
159. Ryu JK, Cho T, Choi HB, Jantaratnotai N, McLarnon JG (2015) Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer’s disease. J Neuroinflammation 12:144
160. Morrison RS, Kinoshita Y, Johnson MD, Guo W, Garden GA (2003) p53-dependent cell death signaling in neurons. Neurochem Res 28:15–27
161. Culmsee C, Mattson MP (2005) p53 in neuronal apoptosis. Biochem Biophys Res Commun 331:761–777
162. Chang JR, Ghafouri M, Mukerjee R, Bagashev A, Chabrashvili T, Sawaya BE (2012) Role of p53 in neurodegenerative diseases. Neurodegener Dis 9:68–80
163. Lanni C, Uberti D, Racchi M, Govoni S, Memo M (2007) Unfolded p53: a potential biomarker for Alzheimer’s disease. J Alzheimers Dis JAD 12:93–99
164. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297
165. Hermeking H (2012) MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 12:613–626
166. Eun B, Cho B, Moon Y, Kim SY, Kim K, Kim H et al (2010) Induction of neuronal apoptosis by expression of Hes6 via p53-dependent pathway. Brain Res 1313:1–8
167. Hooper C, Meimaridou E, Tavassoli M, Melino G, Lovestone S, Killick R (2007) p53 is upregulated in Alzheimer’s disease and induces tau phosphorylation in HEK293a cells. Neurosci Lett 418:34–37
168. Maddocks ODK, Vousden KH (2011) Metabolic regulation by p53. J Mol Med Berl Ger 89:237–245
169. Vousden KH (2010) Alternative fuel—another role for p53 in the regulation of metabolism. Proc Natl Acad Sci U S A 107:7117–7118
170. Cai D (2013) Neuroinflammation and neurodegeneration in overnutrition-induced diseases. Trends Endocrinol Metab TEM 24:40–47
171. Buizza L, Prandelli C, Bonini SA, Delbarba A, Cenini G, Lanni C et al (2013) Conformational altered p53 affects neuronal function: relevance for the response to toxic insult and growth-associated protein 43 expression. Cell Death Dis 4:e484
172. Stanga S, Lanni C, Govoni S, Uberti D, D’Orazi G, Racchi M (2010) Unfolded p53 in the pathogenesis of Alzheimer’s disease: is HIPK2 the link? Aging 2:545–554
173. Bendotti C, Baldessari S, Pende M, Southgate T, Guglielmetti F, Samanin R (1997) Relationship between GAP-43 expression in the dentate gyrus and synaptic reorganization of hippocampal mossy fibres in rats treated with kainic acid. Eur J Neurosci 9:93–101
174. Ambros V, Chen X (2007) The regulation of genes and genomes by small RNAs. Dev Camb Engl 134:1635–1641
175. Leung AKL, Sharp PA (2010) MicroRNA functions in stress responses. Mol Cell 40:205–215
176. Mendell JT, Olson EN (2012) MicroRNAs in stress signaling and human disease. Cell 148:1172–1187
177. Holcik M, Sonenberg N (2005) Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 6:318–327
178. Vojta A, Zoldoš V (2013) Adaptation or malignant transformation: the two faces of epigenetically mediated response to stress. Biomed Res Int 2013:954060
179. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM (2012) p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 149:1536–1548
180. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K (2009) Modulation of microRNA processing by p53. Nature 460:529–533
181. Suzuki HI, Miyazono K (2010) Dynamics of microRNA biogenesis: crosstalk between p53 network and microRNA processing pathway. J Mol Med Berl Ger 88:1085–1094